Native and ß-cyclodextrin-enclosed curcumin: Entrapment within liposomes and their in vitro cytotoxicity in lung and colon cancer

Drug Delivery

Volumn 19, Issue 7, 2012, Pages 346-353

  Rahman, S ^a   Cao, S ^b   Steadman, K J ^a   Wei, M ^b   Parekh, H S ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

Author keywords

cyclodextrin; Anticancer; curcumin; drug entrapment; liposome

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BETA CYCLODEXTRIN; CURCUMIN; LIPOSOME; METHANOL; WATER; ANTINEOPLASTIC AGENT; BETA CYCLODEXTRIN DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOCOMPATIBILITY; CANCER CELL CULTURE; CELL ASSAY; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; FILM; HUMAN; HUMAN CELL; HYDRATION; HYDROPHILICITY; HYDROPHOBICITY; IN VITRO STUDY; INFRARED SPECTROSCOPY; LUNG CANCER; PARTICLE SIZE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; ULTRAVIOLET SPECTROSCOPY; X RAY DIFFRACTION; CHEMISTRY; COLON TUMOR; LUNG TUMOR; PATHOLOGY; SOLUBILITY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BETA-CYCLODEXTRINS; CELL LINE, TUMOR; COLONIC NEOPLASMS; CURCUMIN; DRUG STABILITY; HUMANS; LIPOSOMES; LUNG NEOPLASMS; SOLUBILITY;

EID: 84867494034     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2012.721143     Document Type: Article

References (30)

1. Agashe H, Sahoo K, Lagisetty P, Awasthi V. 2011. Cyclodextrin-mediated entrapment of curcuminoid 4-[3,5-bis(2-chlorobenzylidene-4-oxo-piperidine-1-yl)- 4-oxo-2-butenoic acid] or CLEFMA in liposomes for treatment of xenograft lung tumor in rats. Colloids Surf B Biointerfaces 84:329-337.
2. Al-Omar A, Abdou S, De Robertis L, Marsura A, Finance C. 1999. Complexation study and anticellular activity enhancement by doxorubicin- cyclodextrin complexes on a multidrug-resistant adenocarcinoma cell line. Bioorg Med Chem Lett 9:1115-1120. (Pubitemid 29204668)
3. Arima H, Hagiwara Y, Hirayama F, Uekama K. 2006. Enhancement of antitumor effect of doxorubicin by its complexation with γ-cyclodextrin in pegylated liposomes. J Drug Target 14:225-232.
4. Baglole KN, Boland PG, Wagner BD. 2005. Fluorescence enhancement of curcumin upon inclusion into parent and modified cyclodextrins. J. Photochem. Photobiol. A 173:230-237. (Pubitemid 40935796)
5. Bisht S, Feldmann G, Soni S, Ravi R, Karikar C, Maitra A, Maitra A. 2007. Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. J Nanobiotechnology 5:3.
6. Bouquet W, Ceelen W, Fritzinger B, Pattyn P, Peeters M, Remon JP, Vervaet C. 2007. Paclitaxel/β-cyclodextrin complexes for hyperthermic peritoneal perfusion: formulation and stability. Eur. J. Pharm. Biopharm. 66:391-397. (Pubitemid 46756225)
7. Castelli F, Puglisi G, Giammona G, Ventura CA. 1992. Effect of the complexation of some nonsteroidal antiinflammatory drugs with β-cyclodextrin on the interaction with phosphatidylcholine liposomes. Int. J. Pharmaceut. 88:1-8. (Pubitemid 23000402)
8. Fatouros DG, Hatzidimitriou K, Antimisiaris SG. 2001. Liposomes encapsulating prednisolone and prednisolone-cyclodextrin complexes: comparison of membrane integrity and drug release. Eur. J. Pharm. Sci. 13:287-296. (Pubitemid 32522581)
9. Ireson CR, Jones DJ, Orr S, Coughtrie MW, Boocock DJ, Williams ML, Farmer PB, Steward WP, Gescher AJ. 2002. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol Biomarkers Prev 11:105-111. (Pubitemid 34118319)
10. Kaur N, Puri R, Jain SK. 2010. Drug-cyclodextrin-vesicles dual carrier approach for skin targeting of anti-acne agent. AAPS PharmSciTech 11:528-537.
11. Li L, Braiteh FS, Kurzrock R. 2005. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 104:1322-1331. (Pubitemid 41282806)
12. Loftsson T, Brewster ME. 2010. Pharmaceutical applications of cyclodextrins: basic science and product development. J Pharm Pharmacol 62:1607-1621.
13. Maestrelli F, Gonzalez-Rodriguez ML, Rabasco AM, Mura P. 2005. Preparation and characterisation of liposomes encapsulating ketoprofen- cyclodextrin complexes for transdermal drug delivery. Int. J. Pharmaceut. 298:55-67. (Pubitemid 40834315)
14. Maiti K, Mukherjee K, Gantait A, Saha BP, Mukherjee PK. 2007. Curcumin-phospholipid complex: preparation, therapeutic evaluation and pharmacokinetic study in rats. Int. J. Pharmaceut. 330:155-163. (Pubitemid 46097368)
15. Maruyama K. 2011. Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. Adv Drug Deliv Rev 63:161-169.
16. McCormack B, Gregoriadis G. 1994. Drugs-in-cyclodextrins-in liposomes: a novel concept in drug delivery. Int. J. Pharmaceut. 112:249-258. (Pubitemid 24319842)
17. Moghimi SM, Szebeni J. 2003. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 42:463-478. (Pubitemid 37237636)
18. Safavy A, Raisch KP, Mantena S, Sanford LL, Sham SW, Krishna NR, Bonner JA. 2007. Design and development of water-soluble curcumin conjugates as potential anticancer agents. J Med Chem 50:6284-6288.
19. Sakai H, Masada Y, Horinouchi H, Ikeda E, Sou K, Takeoka S, Suematsu M, Takaori M, Kobayashi K, Tsuchida E. 2004. Physiological capacity of the reticuloendothelial system for the degradation of hemoglobin vesicles (artificial oxygen carriers) after massive intravenous doses by daily repeated infusions for 14 days. J Pharmacol Exp Ther 311:874-884. (Pubitemid 39612691)
20. Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, Currens MJ, Seniff D, Boyd MR. 1988. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 48:4827-4833.
21. Shaikh J, Ankola DD, Beniwal V, Singh D, Kumar MN. 2009. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sci 37:223-230.
22. Sharma RA, Gescher AJ, Steward WP. 2005. Curcumin: the story so far. Eur J Cancer 41:1955-1968. (Pubitemid 41557681)
23. Takahashi M, Uechi S, Takara K, Asikin Y, Wada K. 2009. Evaluation of an oral carrier system in rats: bioavailability and antioxidant properties of liposome-encapsulated curcumin. J Agric Food Chem 57:9141-9146.
24. Tang B, Ma L, Wang HY, Zhang GY. 2002. Study on the supramolecular interaction of curcumin and β-cyclodextrin by spectrophotometry and its analytical application. J Agric Food Chem 50:1355-1361. (Pubitemid 34233191)
25. Tnesen HH, Mason M, Loftsson T. 2002. Studies of curcumin and curcuminoids. XXVII. Cyclodextrin complexation: solubility, chemical and photochemical stability. Int J Pharm 244:127-135. (Pubitemid 35245453)
26. Wang Z, Leung MH, Kee TW, English DS. 2010. The role of charge in the surfactant-assisted stabilization of the natural product curcumin. Langmuir 26:5520-5526.
27. Yadav VR, Suresh S, Devi K, Yadav S. 2009. Effect of cyclodextrin complexation of curcumin on its solubility and antiangiogenic and anti-inflammatory activity in rat colitis model. AAPS PharmSciTech 10:752-762.
28. Yallapu MM, Jaggi M, Chauhan SC. 2010. β-Cyclodextrin-curcumin self-assembly enhances curcumin delivery in prostate cancer cells. Colloids Surf B Biointerfaces 79:113-125.
29. Yang T, Choi MK, Cui FD, Kim JS, Chung SJ, Shim CK, Kim DD. 2007. Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. J Control Release 120:169-177. (Pubitemid 47061489)
30. Zhou H, Beevers CS, Huang S. 2011. The targets of curcumin. Curr Drug Targets 12:332-347.